Cargando…

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

Background: Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related deaths worldwide. Epidermal Growth Factor Receptor (EGFR)-mutated patients usually benefit from TKIs treatment, but a significant portion show unresponsiveness due to primary resistance mechanisms. We investigated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canale, Matteo, Petracci, Elisabetta, Delmonte, Angelo, Bronte, Giuseppe, Chiadini, Elisa, Ludovini, Vienna, Dubini, Alessandra, Papi, Maximilian, Baglivo, Sara, De Luigi, Nicoletta, Verlicchi, Alberto, Chiari, Rita, Landi, Lorenza, Metro, Giulio, Burgio, Marco Angelo, Crinò, Lucio, Ulivi, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230306/ https://www.ncbi.nlm.nih.gov/pubmed/32272775 http://dx.doi.org/10.3390/jcm9041047

Ejemplares similares

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR
por: Siggillino, Annamaria, et al.
Publicado: (2020)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
por: Ulivi, Paola, et al.
Publicado: (2021)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer
por: Verlicchi, Alberto, et al.
Publicado: (2023)

Unveiling mutational dynamics in non‐small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA
por: Pasini, Luigi, et al.
Publicado: (2021)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer
por: De Matteis, Serena, et al.
Publicado: (2019)

Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer
por: Andrikou, Kalliopi, et al.
Publicado: (2023)

High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022)

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2020)

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma
por: Gianni, Caterina, et al.
Publicado: (2021)

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
por: Ulivi, Paola, et al.
Publicado: (2022)

Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2022)

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
por: Ricciuti, Biagio, et al.
Publicado: (2015)

Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors
por: Bronte, Giuseppe, et al.
Publicado: (2021)

High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
por: Ludovini, Vienna, et al.
Publicado: (2021)

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
por: Ricciuti, Biagio, et al.
Publicado: (2017)

Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy
por: Baglivo, Sara, et al.
Publicado: (2021)

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report
por: Metro, Giulio, et al.
Publicado: (2015)

Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis
por: Ludovini, Vienna, et al.
Publicado: (2016)

Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review
por: Metro, Giulio, et al.
Publicado: (2020)

Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
por: Koulouris, Andreas, et al.
Publicado: (2022)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)

Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer
por: Mandarano, Martina, et al.
Publicado: (2021)

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
por: Metro, Giulio, et al.
Publicado: (2021)

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study
por: Ludovini, Vienna, et al.
Publicado: (2017)

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
por: Nicolini, Fabio, et al.
Publicado: (2020)

Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
por: Nicolini, Fabio, et al.
Publicado: (2020)

Non-coding RNAs in lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2014)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Erratum to: ‘Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology’
por: Bianconi, Fortunato, et al.
Publicado: (2016)

Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations
por: Su, Chunxia, et al.
Publicado: (2022)

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
por: Qin, Kang, et al.
Publicado: (2020)

Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool
por: Mandarano, Martina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tq5mpnh0qtq7aab38svaqqkc3s